31 results about "Respiration Disorders" patented technology

Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).

The present disclosure describes systems and methods for assessing heart and respiratory disorders in a patient using a video analysis tool to analyze video data taken of the patients neck region. The video analysis tool allows for an accurate, objective assessment of the patient. In some aspects of the present disclosure, a clinician may capture video data of the patients neck region and run the video analysis tool. Additionally or alternatively, the system may be implemented remotely whereby the video analysis tool may be executed remotely from the video recording device. The video analysis tool extracts pulsatile signals in the neck region from the video data and determines pulsatile signals of interest for assessing heart and respiratory disorders in the patient. The video analysis tool generates assessment data based on the pulsatile signals of interest.

The application discloses a mixed preparation for preventing and treating porcine reproductive and respiratory syndrome virus (PRRSV) infection, a preparation method and application thereof, and belongs to the technical field of biological and animal epidemic disease prevention and treatment. The application provides a mixed preparation for preventing and treating PRRSV infection, a preparation method and application thereof, and sequences of two strains of nanobodies and pig IgG1 Fc contained in the mixed preparation, and in-vivo anti-PRRSV infection activity of the mixed preparation is evaluated. The mixed preparation is applied to prevention and treatment of PRRSV infected pigs, and provides a new strategy and preparation for development of a therapeutic drug for the disease, and has a good market application prospect.

An apparatus for treating respiratory disorders in a patient is disclosed. The apparatus includes a pressure generator configured to deliver a flow of air at positive pressure through a patient interface to an airway of the patient, a sensor configured to generate a signal representative of a respiratory flow of the patient, and a controller. And a controller configured to control the pressure generator to deliver a ventilation therapy with a base pressure and pressure support through the patient interface, an apnea being detected from the signal representative of a respiratory flow of the patient, controlling the pressure generator to deliver one or more detected breaths to the patient during the apnea, determining patency of the airway of the patient from a waveform of the respiratory flow signal responsive to one of the one or more detected breaths, an effective duration of the apnea is calculated based on the patency of the airway, and a setpoint of the base pressure for the ventilation therapy is adjusted in response to the apnea based on the effective duration of the apnea.

A respiratory pressure therapy (RPT) system may be configured to direct a flow of air to a therapeutic pressure above atmospheric pressure to a patient interface worn by a patient to treat a respiratory disorder The RPT system may include: a component that at least partly forms a passage for the flow of air at the therapeutic pressure, the component being one of the patient interface, a flow generator including a blower, an air circuit, or a humidifier; and a vaporization device that includes: a vaporization module including a vaporizer and a heating element; and a reservoir attached to the vaporization module, and the reservoir being configured to store water and provide water to the vaporizer for vaporization during use, wherein at least a portion of the vaporizer is exposed to the passage for the flow of air at the therapeutic pressure.

The invention relates to the technical field of respiratory system disease diagnosis, in particular to a respiratory disorder onset risk prediction method and system. By combining the multiple groups of indexes, early-stage evaluation can be effectively carried out on the respiratory disorder onset risk, and the obstructive respiratory arrest probability and the onset degree can be more intuitively determined through score data, so that the overall automatic prediction of respiratory disorder onset is realized.

The application provides a respiratory disorder evaluation system and method based on non-contact electrocardio, wherein the system comprises a non-contact electrocardio acquisition device, a non-contact electrocardio signal quality evaluation module, a respiratory signal low-frequency energy threshold discrimination module and a non-contact electrocardio respiratory signal extraction and respiratory disorder evaluation module. The system can acquire the electrocardio and respiratory coupling signal of a patient through a layer of clothes. Compared with the traditional contact wet electrode measurement method, the non-contact measurement method has the advantages of long-term monitoring and high comfort. The signal characteristics can be extracted according to the characteristics of the non-contact electrocardio signal, and the method has the advantage of high accuracy. The method uses different respiratory signal extraction methods for two cases. After the respiratory signal extraction is completed, the respiratory disorder event is judged. Based on the characteristics of the non-contact electrocardio, the signal processing related tasks can be efficiently and accurately completed.

A patient interface for treating a patient with a respiratory disorder includes: an RPT device including an electrically powered blower configured to generate pressurized breathable air; a user interface structure configured to engage against the patient's face, the user interface structure at least partially forming an inflation chamber, the inflation chamber configured to receive the pressurized breathable air; a head-mounted interface configured to substantially cover an eye of the patient; a flow generator housing at least partially enclosing the head mounted interface and the motorized blower and connected to the plenum, the flow generator housing including at least one air opening to receive ambient air for delivery to the RPT device; and a positioning and stabilizing structure configured to maintain the user interface structure in a therapeutically effective position.

In certain example embodiments, a system and / or method of guiding transitions between therapy modes in connection with the treatment and / or diagnosis of a patient for a respiratory disorder is / are provided. Respiratory disorder treatment according to a first therapy mode is provided. Input indicating a second therapy mode to be transitioned to following provision of the first therapy mode is received, with the second therapy mode being different from the first therapy mode. At least one default treatment parameter suitable for the second therapy mode is assigned or calculated. Each default treatment parameter of the second therapy mode is presented, with each default treatment parameter being adjustable by an operator during the presenting. Transitioning from the first therapy mode to the second therapy mode is performed by providing respiratory disorder treatment in accordance with the second therapy mode and each default treatment parameter and any adjustments made thereto prior to the transitioning. Advantageously, the chances of a patient being disturbed by transitioning from mode-to-mode are reduced.

This invention relates to the field of sleep monitoring data fusion processing technology, and discloses a sleep monitoring method based on the fusion of non-invasive brain oxygen saturation (AHI) and multiple physiological parameters. The method includes: S1, simultaneously acquiring multiple physiological parameter signals during the subject's sleep; S2, extracting and analyzing the AHI signal to generate multiple characterization markers; S3, identifying respiratory events related to the subject's apnea information from the respiratory signal and pulse oximetry signal, calculating the apnea-hypopnea index (AHI); and performing correlation analysis on the identified respiratory events and multiple characterization markers to calculate a correlation coefficient; S4, obtaining a comprehensive sleep monitoring assessment report based on the correlation coefficient and the AHI to determine the severity of the subject's current respiratory disturbance and the risk of brain tissue hypoxia. By improving the effectiveness of AHI in non-invasive brain oxygen saturation monitoring, the confirmatory nature of non-invasive brain oxygen saturation information in the respiratory correlation diagnosis during sleep monitoring is ensured.

The present invention relates to devices with power source connections for treating respiratory disorders. Respiratory devices, such as ventilators, for use in treating respiratory disorders and for preventing respiratory disorders are configured to be powered from a number of different power sources including an internal battery, an external battery, an alternating current power source, or a direct current power source. The device can be electrically connected to a plurality of external batteries in a string, and power from each external battery is used in turn along the string. A controller of the respiratory device is configured to detect the connection of the different power sources, and control the use of the different power sources using a power priority scheme. The controller can determine an estimate of the total available battery capacity from all electrically connected batteries, and display the total battery capacity on a user interface display of the device.

The invention relates to an alcohol-free, high-lasting ambient fragrance. Since the ambient fragrance of the invention, containing the natural ingredient, does not contain alcohol, said fragrance can be easily used by the individuals suffering from migraine and respiratory disorders.

The invention relates to metered dose inhaler comprising a stable pharmaceutical composition of fluticasone or its pharmaceutically acceptable ester contained in a canister fitted with a metering valve, an actuator and dose counter. The invention also relates to a process for preparing said pharmaceutical composition and its use in the treatment of respiratory disorders such as asthma in a subject (e.g., a human).

This technology relates to a forehead cooling system configured for use with a patient interface to assist in the treatment of sleep and respiratory disorders. Embodiments of this technology include fluid cooling systems such as air cooling and water cooling. Other embodiments utilize phase change materials and thermoelectric coolers. In some embodiments, the forehead cooling system may be mounted on a positioning and stabilization structure.

The present disclosure provides methods of treating patients having a respiratory disorder, methods of identifying subjects having an increased risk of developing a respiratory disorder, and methods of detecting human Arachidonate 15-Lipoxygenase (ALOX15) variant nucleic acid molecules and variant polypeptides.

The present application relates to a kind of voiceprint identification method, device and man-machine interaction equipment under the embrace type signal field, belong to wearable device technical field, the method is by collecting the voice signal of target user, and synchronously obtain at least contain wrist movement acceleration, skin surface vibration frequency and blood oxygen saturation physiological signal;The environmental noise separation processing of the voice signal is carried out, extracts the voiceprint feature vector of the base frequency jitter rate and resonance peak migration trajectory contained in the voice signal;The physiological signal is after time-frequency conversion with voiceprint feature vector is carried out feature fusion, generates and generates the feature map containing user identity identification and physiological state parameter;The voice feature section and physiological feature section in the feature map are carried out event judgment, realize complex environment under the voiceprint identification precision of improvement, while, realize user identity determination and the real-time early warning effect of physiological abnormality such as respiratory disorder.

A respiratory pressure therapy system for treating a patient with a respiratory disorder includes a patient interface, a blower configured to generate a pressurized flow of gas, the blower configured to be connected to the patient interface such that the blower is supported on the patient's head by the patient interface, and a muffler system provided to the patient interface and / or the blower, the muffler system configured and arranged to reduce noise from the blower and / or enhance patient comfort, wherein the muffler system comprises a blower outlet muffler configured to connect to the patient interface and the blower, wherein the blower outlet muffler is configured to form an airflow path to convey the pressurized flow of gas from a blower outlet of the blower to an inlet opening of the patient interface.

The disclosure provides stable liquid non-aqueous epinephrine and epinephrine prodrug formulations, including non-aqueous liquid dipivefrin HCl formulations. The formulations are suitable for use as oral spray, oral film, liquid-filled capsules or buccal, lingual, or sublingual drop formulation. The oral spray, oral film and liquid-filled capsule can be placed on the tongue, under the tongue (sublingual) or in the buccal space. Preferably, the oral spray is a sublingual spray. The disclosure provides a method for systemic delivery of a therapeutically effective amount of epinephrine to a subject comprising orally administering a non-aqueous liquid formulation of an epinephrine prodrug, such as dipivefrin HCl to the subject. The disclosure also includes a method of treatment of a disease amenable to treatment by in vivo delivery of systemic epinephrine comprising administering the disclosed formulations. The disease can be a respiratory disorder, type I allergic reactions including anaphylaxis and urticaria, or the disease can be cancer or a microbial infection.

Lightweight, portable oxygen concentrators that operate rising an ultra rapid, sub one second, adsorption cycle based on advanced molecular sieve materials are disclosed. The amount of sieve material utilized is a fraction of that used in conventional portable devices. This dramatically reduces the volume, weight, and cost of the device. Innovations in valve configuration, moisture control, case and battery design, and replaceable sieve module are described. Patients with breathing disorders and others requiring medical oxygen are provided with a long lasting, low cost alternative to existing portable oxygen supply devices.

The application provides a multiplex fluorescent quantitative primer and probe combination for differentiating and diagnosing porcine reproductive and respiratory syndrome virus (PRRSV) strains and application thereof, including three groups of primers and probes for PRRSV, NADC30 and NADC34 respectively; further including primers and probes for 18S rRNA sequence as internal standards in detection. Further provided is a multiplex fluorescent quantitative RT-PCR kit for differentiating and diagnosing typical or atypical respiratory and reproductive disorders of pigs caused by different types of PRRSV strains, including a reaction solution packaged by the kit, and each primer and corresponding probe group is packaged or mixedly packaged. The application can simultaneously differentiate and diagnose various high-incidence pathogenic strains (PRRSV, NADC30 and NADC34) of porcine reproductive and respiratory syndrome through design, optimization and screening of primers and probes, and the amplification of the three target genes does not interfere with each other, and the application has high specificity, high sensitivity, good repeatability, can accurately diagnose viral infection and has high application value and huge economic benefits.

1. The name of the design product: humidification chamber adapter (ICU FA5). 2. The use of the design product: the design product is used as an accessory of the ventilation treatment equipment for apnea and respiratory disorder diseases. 3. The design points of the design product: in shape. 4. The picture or photo that best shows the design points: perspective view 1.

Examples include a treatment system for providing disordered breathing therapy to a sleeping patient, the system comprising at least one first stimulation lead, at least one second stimulation lead, and an implanted therapy controller configured to couple to the leads and to provide at least one phrenic-nerve electrical stimulation to a phrenic nerve of a patient via the at least one first stimulation lead, provide at least one hypoglossal-nerve electrical stimulation to a hypoglossal nerve of the patient via the at least one second stimulation lead, and coordinate a relative timing of the electrical stimulation to the hypoglossal nerve with the electrical stimulation to the phrenic nerve of the patient.

Examples of the disclosure include a system for treating disordered breathing in a patient, including an electrical-pulse generator (IPG) to generate an electrical stimulation and including a controller and a power source, a lead including a first sensor, and a second sensor, the controller being configured to provide, via the lead, first electrical stimulation to a target nerve including a phrenic nerve, receive, from the lead, respiratory information indicative of a respiratory parameter of the patient, determine, based on the respiratory information, a therapy-specific indicator indicative of an effect of the stimulation, receive, from the at least one second sensor, non-respiratory information, determine, based on the non-respiratory information, a patient-specific indicator relating to at least one patient condition, modify, based on at least one of the indicators, at least one parameter of the stimulation, and provide, via the lead, at least one second electrical stimulation having the modified parameter.

The invention belongs to the technical field of sleep breathing, and discloses a multi-modal evaluation method, device and equipment for sleep dyspnea and a medium, and the method comprises the steps: obtaining a multi-modal feature sequence; obtaining a context sensing detection module and individual physiological parameters of the user, obtaining a structured respiratory event sequence at each time point, and performing dynamic fine adjustment by the context sensing detection module according to the individual physiological parameters of the user; and a severity quantification module is obtained, the severity feature vector and the individual physiological parameters of the user are input into the severity quantification module, and a severity score of the respiratory event is obtained. And accurate detection, fine classification and individualized adaptation of sleep breathing events are realized. By using the severity quantification module, the severity score of the respiratory event is obtained, and the severity of each event can be continuously quantified.

The present technology relates to a forehead cooling system configured for use with a patient interface to aid in the treatment of sleep and respiratory disorders. Examples of the present technology include fluid cooling systems, such as air cooling and water cooling. Other examples use phase change materials and thermoelectric coolers. In some examples, the forehead cooling system may be attached to a positioning and stabilizing structure.

A device for treating respiratory distress in a patient is disclosed. The device includes a pressure generator configured to deliver a positive pressure airflow to the patient's airway via a patient interface, a sensor configured to generate a signal representing the patient's respiratory flow, and a controller. The controller is configured to control the pressure generator to deliver ventilation therapy with baseline pressure and pressure support via the patient interface, detect apnea by the signal representing the patient's respiratory flow, control the pressure generator to deliver one or more probe breaths to the patient during the apnea, determine airway patency by the waveform of the respiratory flow signal in response to one of the one or more probe breaths, calculate the effective duration of the apnea based on the airway patency, and adjust a setpoint of the baseline pressure for the ventilation therapy in response to the apnea based on the effective duration of the apnea.

The present disclosure provides methods of treating patients having a respiratory disorder, methods of identifying subjects having an increased risk of developing a respiratory disorder, and methods of detecting human Arachidonate 15-Lipoxygenase (ALOX15) variant nucleic acid molecules and variant polypeptides.

A non-invasive technique for enhancing the delivery of botulinum toxins through the skin, utilizing low-frequency ultrasound as a pretreatment, is provided. The ultrasound- facilitated transdermal delivery approach provides an efficient, comfortable and needle-free alternative to conventional injection-based administration of botulinum toxins, and is applicable to a wide range of therapeutic and cosmetic uses, including, reducing or modulating sweat gland activity, relaxing or inhibiting muscle activity, alleviating pain, minimizing wrinkles or fine lines, and treating or preventing pathologies such as neuromuscular and neurological disorders, glandular dysfunction, urological conditions, ophthalmological disorders, gastrointestinal conditions and / or respiratory disorders

To provide methods, apparatus, and systems for treating a respiratory disorder in a patient.SOLUTION: An apparatus comprises: a pressure generator configured to generate a flow of air so as to provide ventilatory support to the patient; a transducer configured to generate a flow signal representing a property of the flow of air; and a controller. The controller is configured to: analyze the flow signal to estimate the inspiratory volume and the expiratory volume of a breath of the patient; and servo-control the degree of ventilatory support to adjust an estimated tidal volume toward a target tidal volume. A gain of the servo-control is dependent on a difference between the estimated inspiratory volume and the estimated expiratory volume.SELECTED DRAWING: Figure 9

Systems and methods provide for monitoring respiratory disorder treatment provided by a therapy device (4000). The pressure device may deliver pressurized air to a patient interface that, in use, connects to a patient. The sensor may monitor a characteristic of the pressurized air. The processor may control the pressure device to deliver air at a therapeutic pressure in response to an adverse event. The delivered therapeutic pressure may be maintained within a therapeutic pressure range between a minimum therapeutic pressure and a maximum therapeutic pressure. An adverse event may be detected based on air characteristics monitored during a treatment session. A count of detected adverse events occurring during pressure delivery within a given treatment pressure range within a treatment session may be evaluated. A suggestion including a parameter change may be generated or an automated operation may be performed in response to a count of detected adverse events for a subsequent therapy session.